Abstract 496P
Background
Fruquintinib (F, a highly selective VEGFR inhibitor) plus sintilimab (S, an anti-PD-1 monoclonal antibody) showed promising antitumor activity in both pre-clinical and clinical studies. Here, we reported the results of advanced NSCLC cohort with PD-L1-positive expression in an open-label, multi-cohort, single-arm phase 2 study to evaluate the safety and efficacy of F+S.
Methods
Eligible advanced NSCLC pts were those who failed, could not tolerate, were not suitable or unwilling to receive standard treatment; were PD-L1 positive (defined as PD-L1 TPS expression ≥1%); and were without EGFR, ALK or ROS1 genetic alteration if non-sq-NSCLC. Enrolled pts received 21-day cycles of F (5 mg, orally QD, 2 weeks on/1 week off) plus S (200 mg IV, Q3W) until disease progression or intolerable toxicity or the maximum duration of treatment with S (24 mo). The primary endpoint was ORR per RECIST 1.1.
Results
As of May 31, 2023, 13 treatment-naïve pts were enrolled and received treatment of F+S. Median age, 69 yrs (range: 36-75); male, 12 (92.3%) pts; sq-NSCLC, 7 (53.8%) pts; adenocarcinoma, 6 (46.2%) pts. Pts with PD-L1 TPS ≥50% and <50% were 6 (46.2%) and 7 (53.8%), respectively. The median follow-up duration was 17.7 (95%CI: 10.4, 18.4) mo. Among 12 pts with at least one post-baseline tumor assessment, the confirmed ORR was 50.0% (95%CI: 21.1%, 78.9%); DCR was 100% (95%CI: 73.5%, 100%); the median DoR, PFS, and OS were all not reached. 15mo-PFS rate was 55.9% (95%CI: 24.0%, 79.0%), and 18mo-OS rate was 60.6% (95%CI: 29.4%, 81.4%). When stratified by PD-L1 level (TPS ≥50% vs <50%), 15mo-PFS rate were 66.7% (95%CI: 19.5%, 90.4%) vs 42.9% (95%CI: 5.8%, 77.7%), 18mo-OS rate were 66.7% (95%CI: 19.5%, 90.4%) vs 53.6% (95%CI: 13.2%, 82.5%). The median treatment duration of F and S were both 8.3 mo (range 0.7-18.6). All pts experienced TEAEs, and the most common (≥10%) ≥G3 treatment related TEAE was only blood pressure increased (15.4%).
Conclusions
F plus S showed a promising antitumor activity and manageable toxicity for advanced NSCLC with PD-L1-positive status. This study might represent a potential treatment option for these pts, especially for pts who can not tolerate chemotherapy.
Clinical trial identification
NCT03903705.
Editorial acknowledgement
Editorial support is provided by Ye Liu from HUTCHMED Limited.
Legal entity responsible for the study
HUTCHMED Limited.
Funding
HUTCHMED Limited.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
238P - Enfortumab-vedotin for metastatic urothelial carcinoma refractory to platinum-based chemotherapy and immune checkpoint inhibitors: A single institution experience
Presenter: Yuki Endo
Session: Poster Display
Resources:
Abstract
239P - Elevated baseline C-reactive protein is a prognostic indicator for OS in patients with metastatic non clear cell renal cell carcinoma treated with systemic therapy
Presenter: Ryuichi Mizuno
Session: Poster Display
Resources:
Abstract
240P - Efficacy and safety of first-line combination therapy with ipilimumab + nivolumab for metastatic renal cell carcinoma in a single institution in Japan
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
241P - First-line cabozantinib in metastatic renal cell carcinoma (mRCC): A real-world exploratory study from eastern India
Presenter: Tamojit Chaudhuri
Session: Poster Display
Resources:
Abstract
244P - Clinicopathologic feature and treatment outcome of metastatic non clear cell kidney cancer: A single centre experience from India
Presenter: Somnath Roy
Session: Poster Display
Resources:
Abstract
245P - The role of TGF-β in the formation of the protumor phenotype of circulating neutrophils at different stages of renal cancer
Presenter: Ilseya Myagdieva
Session: Poster Display
Resources:
Abstract
246P - Impact of renal impairment on first-line treatment in metastatic urothelial cancer
Presenter: Stephanie Wakeling
Session: Poster Display
Resources:
Abstract
247P - Adjuvant chemoradiotherapy in the management of bladder adenocarcinoma compared to multiple treatment modalities
Presenter: Othman Mohammed
Session: Poster Display
Resources:
Abstract
248P - Screening zinc homeostasis-related genes identifies metallothionein 1H (MT1H) as a potential prognostic biomarker in clear cell renal cell carcinoma (ccRCC)
Presenter: Eyad Al Masoud
Session: Poster Display
Resources:
Abstract
249P - The prognostic utility of Progestogen associated Endometrial protein (PAEP) gene expression in clear cell renal cell carcinoma (ccRCC)
Presenter: Leen Lataifeh
Session: Poster Display
Resources:
Abstract